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Introduction 
 
Variant Creutzfeldt-Jakob disease (vCJD) is one 
of the transmissible spongiform encephalo-
pathies, which affect humans and other mam-
mals. These neurodegenerative conditions, also 
known as prion diseases, are potentially trans-
missible, although most human diseases are 
apparently not acquired (Table 1) [1]. They 
share a common molecular abnormality: a post-
translational conformational change in a normal 
host protein (the prion protein, encoded in hu-
mans by the prion protein (PRNP) gene on chro-
mosome 20). Transmissibility necessitates an 
infectious agent that has been termed the 
‘prion’; its nature has not yet been fully charac-
terised [2]. According to the prion hypothesis, 
the prion consists entirely or mainly of the ab-
normally folded prion protein (designated PrPSc, 
the normal form being designated PrPc). The 
abnormal prion protein appears to cause a cas-
cade of misfolding in the normal cellular prion, 
similarly altering its conformational structure 
and propagating the disease.  
  
Given the large numbers of BSE cases in the UK 
and the great potential exposure of the UK 
population to BSE infectivity in food between 
1985 and 1996 [3], the relatively small number 
of UK vCJD cases identified to date (N=175) 
stands in need of explanation [4]. Epidemiologi-
cal, human clinical and animal experimental 
studies have led to a greater, although incom-
plete, understanding of the size of the epidemic 
and have informed precautionary measures. 
  
BSE and vCJD 
 
In the UK, the National CJD Research and Sur-
veillance Unit was established in Edinburgh in 
1990 in response to concerns for public health 
over the emergence of bovine spongiform en-
cephalopathy (BSE) in cattle. However, there 
were experimental data suggesting a barrier to 
transmission of prion diseases between species 
which provided a degree of reassurance about 
the risk to the human population [5].  
 
Epidemiology of vCJD 
 
The first cases of vCJD were reported in 1996 
[6]. vCJD cases were initially differentiated from 
sporadic CJD (sCJD) by their younger age of on-
set and differing pathological features (Table 2) 
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[7]. 
 
There are documented young onset sCJD cases 
from as young as 18 years [8], but this is very 
rare; UK CJD surveillance since 1990 has found 
only two of 1147 sCJD cases to have been un-
der 30 years of age [4]. Patients with vCJD were 
initially only found within the UK population, 
although gradually other countries have re-
ported cases.  Currently 218 cases have been 
reported worldwide, 175 of whom were, or had 
been, UK residents during the high risk period 
(Table 3) [4,9]. The temporal relationship to the 
BSE outbreak in the UK supports the direct link 
between the two conditions (Figure 1). The epi-
demiological link between the use of meat and 
bone meal in bovine feeds and the occurrence 
of BSE has been established [10]. The annual 
number of reported deaths from vCJD in the UK 
has fallen since 2000. One explanation would 
be the success of the control measures intro-
duced; there have been no cases of vCJD from 
the UK in those born after the bovine offal ban 
was introduced in 1989 [11]. 
 
Infectious agent 
 
Infectious diseases can be characterised in 
 
 
 
Table 1. Human and animal Transmissible spongiform encephalopathies (TSEs) and the year they were 
reported 
Human TSEs First reported Animal TSEs First reported 
Sporadic CJD 1921 Sheep Scrapie 1730 
Familial CJD 1924 Goat Scrapie 1872 
Gerstmann-Straussler-
Scheinker disease (familial) 
1936 Chronic wasting disease (Elk/Mule) 1967 
Kuru 1955 Bovine spongiform encephalopathy 1986 
Iatrogenic CJD 1974 Feline spongiform encephalopathy 1990 
Fatal Familial insomnia 1986     
Variant CJD 1996     
Table 2. Clinical differences between Sporadic and Variant CJD 
  Sporadic CJD Variant CJD 
Mean age at death (years) 67 29 
Mean duration of illness (months) 4 13 
Rapidly progressive dementia Common Rare 
Psychiatric symptoms at onset Rare Common 
Sensory symptoms Rare Common 
Table 3. Variant CJD cases worldwide (August 2011) 
  Number of primary cases (Alive) Number of secondary cases: blood 
transfusion (Alive) 
UK and Northern Ireland 172 (3) 3 (0) 
France 25 (0) - 
Spain 5 (0) - 
Republic of Ireland 4 (0) - 
USA 3 (0) - 
Netherlands 3 (0) - 
Portugal 2 (0) - 
Italy 2 (0) - 
Canada 2 (1) - 
Saudi Arabia 1 (0) - 
Japan 1 (0) - 
Taiwan 1(0) - 
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terms of the infective agent, the process of 
transmission and the characteristics of the indi-
vidual developing the condition. Our knowledge 
of the infective agent is limited, however animal 
studies give us some information about prion 
disease transmission. 
 
Different types of transmissible prion disease 
are thought to be due to different strains of the 
prion, although the basis of agent strain is not 
fully understood. Successful prion disease 
transmission is thought to be dependant, at 
least in part, on the strain of the prion agent 
and its genetic compatibility with the host. Ex-
perimental transmission studies in mice have 
shown that the strain of agent causing vCJD has 
identical properties to that of BSE, which differ 
to that of scrapie or sCJD [12]. Prion strains vary 
in their ability to be transmitted between differ-
ent species and in the pattern of disease they 
cause among species [13]. 
 
Sheep scrapie strains can be differentiated by 
western blot analysis, but BSE and  vCJD have 
the same biochemical properties. vCJD and BSE 
show a unique isoform on western blot analysis; 
the glycosylation present after PK digestion is 
different to that seen in other forms of CJD 
[14,15].  This suggests that the same agent is 
responsible for both vCJD and BSE. Unlike some 
other prion diseases, these agents show re-
markable stability following transmission even 
after multiple passages into different species. 
Unfortunately, BSE crosses between species 
more readily than scrapie [15].   
 
A species barrier to transmission of some prion 
diseases is well established. This may explain 
why humans apparently have never contracted 
scrapie [16]. Different species have differing 
PrP gene sequences and therefore their PrPc 
structures may vary. These differences in gene 
sequence may provide some explanation for the 
species barrier [16]. Of note, transgenic mice 
expressing human PrP or hamster PrP are sus-
ceptible to BSE inoculation, which is not the 
case in conventional mice [17]. This supports 
the importance of genetic susceptibility in prion 
diseases. However, unlike these controlled ani-
mal experiments, environmental factors play a 
Figure 1. Reported incidence of BSE and vCJD in the UK. Note that the scale on the left is in increments of 5000 cat-
tle. The scale on the right is in increments of 5 vCJD cases. 
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role in human transmission. 
 
Environmental factors 
 
Volume of exposure 
 
A case-control study of vCJD revealed a higher 
reported intake of mechanically recovered beef 
products in cases than controls. This suggests 
an increased potential oral exposure to BSE 
[18] (Chart 2, dietary risk factors). There is a 
risk of recall bias from the relatives of cases. 
However, differences in the incidence of cases 
across the country support the link. A two-fold 
difference was seen between the rate of devel-
opment of vCJD in the North compared to South 
of the UK (rate ratio= 1.94, 95% CI 1.12, 3.36) 
[19]. Two National Dietary Surveys from the 
time period demonstrated significant differ-
ences in diet between these regions. Consump-
tion of mechanically recovered beef products 
was much higher in the North, although the 
overall beef consumption was very similar. This 
information supports the link between both the 
consumption of higher risk beef products, and a 
link to the frequency of their consumption. 
 
Experimental transmission studies have demon-
strated that the volume of inoculum affects the 
likelihood of transmission. In 1995 oral trans-
mission of BSE to sheep and goats was demon-
strated with as little as 0.5g of infective bovine 
brain [10]. Transmission studies in macaques 
have been successful with 5g of orally intro-
duced BSE-infected brain homogenate [20]. A 
2002 study into the lethal challenge required to 
infect hamsters demonstrated a linear rate of 
transmission, which fell with increasing dilution 
of the oral inoculum [21]. This is likely to remain 
the case in humans, but the volume of neces-
sary tissue can only be speculated. 
 
Route of exposure 
 
The risk of developing vCJD may partly relate to 
the route of exposure. The commonest route of 
primary exposure in humans is likely to be oral. 
We know higher rates of transmission are seen 
with brain inoculation than with the same infec-
tive load given orally. In addition IV transfusion 
of whole blood from BSE infected sheep into 
recipient sheep has been shown to transmit 
infection with success rates of 60% [22]. 
 
Since 2003 the Transfusion Medicine Epidemi-
ology Review (TMER) identified four cases of 
vCJD infection in recipients of blood from do-
nors who later went on to develop clinical vCJD 
[23,24]. Three cases showed typical MM homo-
zygosity at codon 129 and presented with the 
same clinical presentation and pathology as 
other vCJD cases. One however, demonstrated 
asymptomatic splenic and lymph node infection 
and was an MV heterozygote at codon 129. 
These four cases were identified from 66 indi-
viduals who had received blood products from 
vCJD donors, only 28 of whom survived more 
than five years after their transfusion [25]. Pa-
tients receiving blood transfusion are commonly 
older with more co-morbidity, leading to their 
requirement for blood and shortened life expec-
tancy. Given the inoculation time in the con-
firmed vCJD cases varied between 5 and 8.5 
years, some of the other patients may have died 
in the pre-clinical phase. Even the ratio of con-
firmed symptomatic cases (4/66) suggests a 
high efficiency of onward infection when com-
pared with the oral route. There is ongoing sur-
veillance of the 18 surviving exposed patients. 
There is a risk of onwards transmission of the 
disease during the asymptomatic phase of the 
illness. 
 
Animal studies comparing vCJD cases con-
tracted via BSE or transfusion suggest no 
change in the pattern of pathology or clinical 
presentation following onward transmission into 
wild-type and transgenic mice [25].   
 
Susceptibility factors 
 
Age 
 
Although the entire UK population is likely to 
have been exposed to BSE in the food chain, 
the majority of vCJD cases are aged less than 
40. This suggests a higher rate of dietary expo-
sure, increased susceptibility to infection or a 
reduced incubation period in this age group. 
One possible explanation is that as part of the 
development of human immune systems there 
is a greater volume of gut-associated lymphoid 
tissues when younger [26]. There is therefore a 
higher volume of tissue to absorb the infected 
material. Asymptomatic infection of lymphoid 
tissue appears to precede neurological disease 
in animals and humans. This process may ex-
plain the broader distribution of PrPSc in vCJD, 
where infectivity is often found in the tonsils 
and spleen, unlike familial and sCJD where 
The molecular epidemiology of variant CJD  
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PrPSc is predominantly only found in neural tis-
sues [27]. 
 
Avrahami and Gabizon studied young and old 
mice inoculated intraperitoneally with prion in-
fected brain tissue [28]. The younger mice de-
veloped clinical signs and reached the terminal 
phase more quickly. They had a shorter incuba-
tion period and developed more marked neuro-
pathological features. PrPSc levels were main-
tained at low levels in the spleens of the older 
mice even at the disease end-point. They sug-
gest the altered peripheral absorption and less 
marked central nervous system response ex-
plain the differences in susceptibility with age. 
Their paper might also suggest variability in in-
cubation time with increasing age, something 
that has not been confirmed in humans with 
vCJD. 
 
Genetic influence 
 
Codon 129: The PRNP gene (OMIM *176640), 
on chromosome 20, encodes for the production 
of human PrPC. There are over 20 reported 
pathological mutations in this gene associated 
with familial CJD.  
 
In 1991 a single nucleotide polymorphism at 
codon 129 on the PRNP gene (rs 1799990) 
was found to be associated with the develop-
ment of CJD linked to the use of cadaveric pitui-
tary hormones [29]. Subsequently MM homozy-
gosity, at codon 129, was noted to influence the 
age of presentation of familial CJD [30]. MM 
homozygosity was also associated with sCJD; 
where 65% of cases were MM homozygotes 
compared to 40% of the normal UK population. 
The difference is most clearly seen in vCJD 
where all 157 pathologically confirmed cases 
have had the MM genotype. This is clearly a very 
strong association, but it is not yet clear 
whether the polymorphism is the major determi-
nant of patients’ susceptibility or only incuba-
tion time (Table 4).   
As discussed earlier there has been one con-
firmed asymptomatic case with an MV genotype 
at codon 129 infected with CJD via blood trans-
fusion [31]. A further asymptomatic case in a 
patient with haemophilia, also of MV genotype, 
has been reported [32]. They had received mul-
tiple blood transfusions and pooled factor VIII 
from a donor who later died from clinical vCJD . 
There has been one patient with MV heterozy-
gosity who presented with symptoms suggestive 
of vCJD. However, their imaging was not typical 
and the patient did not undergo a post mortem 
examination [33]. 
 
Two of three PrP-positive samples in an anony-
mous appendix study had the VV genotype (see 
below) [34]. This suggests the condition can be 
transmitted at least to the lymphoid tissues of 
patients of all genotypes. This could result in 
either a preclinical phase of the illness, before 
the development of neurological disease or a 
sub-clinical infection where patients will not 
progress to develop the condition [35]. Such 
sub-clinical forms of prion disease have been 
seen in animal studies with MM transgenic 
mice, but it is uncertain if this occurs in humans 
[17].  It has been suggested however, that such 
cases are probably necessary to explain the 
observed human data [36]. 
 
It is currently unclear whether PRNP genotypes 
confer only a longer incubation period rather 
than resistance to the disease. Our knowledge 
of the other orally acquired prion disease; Kuru, 
might help answer this question. This disease 
emerged in the 1950s among a remote linguis-
tic cultural group in Papua New Guinea practic-
ing ritual funerary cannibalism. 
 
We know that the maximum incubation period 
for Kuru can exceed 50yrs, with a mean incuba-
tion period of 12yrs [37]. On examining blood 
samples from patients from the peak of the epi-
demic, and more recent samples, an age strati-
fication of codon 129 genotype is seen [38]. 
Table 4. PRNP codon 129 distribution in the UK 
  % MM %MV %VV 
Normal population 29 37 51 12 
Pathologically confirmed Sporadic CJD 
(NCJDSU UK 1990-2005) 4 
65 17 18 
Pathologically confirmed Variant CJD 
(NCJDSU 1995-2010) 4 
  
100  
(N=166) 
0 0 
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The young Kuru patients were mainly of MM or 
VV genotype and the elderly patients were 
mostly MV. Eight of eleven of the more recent 
cases were MV homozygotes; supporting its 
possible effect on prolonging incubation time 
given that exposure should have ended over 40 
years ago when ritual funerary cannibalism was 
outlawed [39,40].  
 
Other genetic factors: In addition to MM homo-
zygosity at codon 129 there have been other 
proposed risk mutations. Bishop et al compared 
PRNP gene sequencing of 118 confirmed vCJD 
cases with 970 blood donor controls and 309 
sCJD cases [41]. They found four patients with 
potentially relevant polymorphisms; two with 
alterations at codon 219 and two at codon 202. 
The first mutation has been known to influence 
the clinical phenotype of cases with the P102L 
mutation in Japan and Korea. The second has 
been reported in one sporadic and one iatro-
genic CJD case in France. A further paper by 
Bishop et al looked at cathepsin D polymor-
phisms in patients with vCJD and UK controls 
[42]. Polymorphisms in this gene have been 
studied in Alzheimer’s disease, where they have 
been linked to disease susceptibility and amy-
loid propogation. They found the TT genotype 
gave a 9.75 odds ratio (CI 1.52-62.47) of devel-
oping vCJD compared to the CT genotype and a 
10.92 odds ratio (CI 1.80-66.26) compared to 
the CC genotype. However, there are wide confi-
dence intervals given that only three vCJD cases 
out of 110 had a TT genotype. 
 
Mead et al looked at the whole genome in their 
association study with 109 definite vCJD cases 
and 10 probable cases [38]. They had 3692 
controls. Despite looking within a similar cohort 
of vCJD patients, from the UK population, their 
genome wide association study implicated two 
different loci. They found two significant ge-
nome wide single nucleotide polymorphisms 
(p<5x10-7) on allelic testing. One was located in 
an intron of PRNP with a moderately strong link-
age disequilibrium to codon 129. The other oc-
curred in the intergenic region between RARB 
(retinoic acid receptor, beta; OMIM *180220) 
and THRB (thyroid hormone receptors, beta; 
OMIM *190160). They suggest retinoic acid 
may act through the receptor encoded by RARB. 
PrP expression in cultured neuronal cells is 
known to be regulated by retinoic acid. The 
power of their analysis was limited by the small 
number of vCJD cases and no other significant 
associations were found. 
 
Predicting the size of the vCJD epidemic 
 
Predicting the number of expected cases of 
vCJD is difficult, and estimated numbers have 
fallen in line with the number of reported cases 
(Figure 2. Predicative modelling of vCJD). The 
most recent modelling by Ghani (2010) predicts 
390 further cases between 2010 and 2179, 
incorporating the potential for secondary trans-
mission of cases [36]. However, despite active 
surveillance it is possible that only patients who 
fit the defined phenotype and pattern of investi-
gations are being diagnosed. The low overall 
post mortem rate in dementia patients and less 
intensive investigation of older patients creates 
the possibility of cases being missed. In addition 
there may be a number of asymptomatic cases 
who may or may not develop neurological dis-
ease. One way of investigating the general 
population is to screen lymphoid tissue samples 
for evidence of prion proteins.    
 
In 2004 a study screening 1,427 anonymous 
tonsil specimens and 11,247 appendix speci-
mens by immuno-histochemistry found three 
appendixes positive for the presence of disease-
associated prion protein [43]. Stored tissue 
samples from within the high risk 1961-85 birth 
cohort were screened from two regions; Scot-
land and South West England. Generalisation of 
the results suggested a prevalence of 292 per 
million (95% CI; 60-853). A second larger study 
of anonymous tonsil specimens conducted in 
2008 was more reassuring [44]. They found no 
abnormal specimens by initially screening with 
two enzyme immunoassays and following up 
any positive results with the more proven tech-
nique of immuno-histochemistry. This study re-
viewed tonsil specimens from a later time pe-
riod, mostly 2006-7 compared to 1995-9 from 
the appendix study (the peak of the BSE epi-
demic). Moreover, the average age of patients 
in the appendicetomy study was four years 
older; giving more time for abnormal proteins to 
propagate. The tonsil study reported a preva-
lence of zero with confidence intervals of 0 to 
289 per million in the 1961-85 cohort. This pre-
dicted prevalence was therefore lower, but con-
sistent with the earlier study. A P value of 0.09 
is given for the comparison of these two preva-
lence estimates. 
 
The most recent tonsil study showed positive 
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PrP staining in one follicle, from one patient, 
when looking at 9160 patients from the 1961-
1985 birth cohort [45]. The prevalence results 
are comparable to the initial appendix study if 
this patient is considered as a positive case or 
the first tonsil study if they are not.  However, all 
these prevalence results assume the tests are 
100% sensitive and specific throughout the in-
cubation period. 
 
Three patients have had removal of lymphoid 
tissue prior to becoming symptomatic of vCJD. 
Two patients had positive immunohistochemis-
try from appendicectomies up to two years prior 
to developing symptoms [46]. The third pa-
tient’s appendix was removed ten years earlier, 
which was negative for PrPSc [43, 46]. Unfortu-
nately, as the average age of appendicetomy is 
22 and tonsillectomies is under ten, the major-
ity of prospective specimens will be from out 
with the highest risk birth cohort limiting further 
similar studies. Currently we do not have a 
screening test for patients with sub-clinical in-
fection. We do however have useful CSF bio-
markers and imaging features to aid diagnosis 
in patients once they develop neurological dis-
ease. 
Biomarkers in vCJD  
 
A large number of CSF biomarkers have been 
found to be elevated in patients with CJD; in-
cluding 14-3-3 protein, S-100 β, tau, and neu-
ron-specific enolase (NSE) [47].  The release of 
these proteins has been shown to follow a bell 
curve with normal concentrations early and late 
in the disease process. Most of these bio-
markers were initially investigated in sCJD and 
have lower efficacy in vCJD. Indeed in vCJD, 
unlike sCJD, biomarkers are not included in the 
WHO diagnostic criteria [7].   
 
14-3-3 proteins are expressed at the synapse of 
neurones. These proteins are detected from 
CSF by western blot, generally relying on visual 
interpretation of the bands. A high agreement in 
interpretation of this analysis between laborato-
ries has previously been shown [48]. We know 
that disorders, including viral and paraneoplas-
tic encephalitis, generalised seizures and 
strokes lead to release of these proteins into 
the CSF. The multi-centre study by Sanchez-
Juan and colleagues showed an 85% sensitivity 
(95% CI 83-87%) in 1457 sCJD cases; in 93 
vCJD cases its sensitivity fell to 40% (95% CI 30-
Figure 2. Published predictions of the size of the vCJD epidemic. The Cooper paper included predictions up to 2010. 
The Clarke and Garske papers include non-MM cases and subclinical infection as indicated. 
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50%) [49]. The specificity is quoted to be around 
92%, but is heavily influenced by the cohort of 
patients being investigated. Interestingly in an 
earlier paper by Green et al had shown that the 
clinical presentation and timing of lumbar punc-
ture did not appear to influence the likelihood of 
a positive 14-3-3 in vCJD [50]. 
 
S-100β, an astrocytic protein, is often used in 
combination with 14-3-3 protein in sCJD. Green 
et al found a 78% sensitive and 76% specific in 
45 vCJD cases and 34 controls [50]. NSE is 
even less sensitive occurring in only six of 
twenty-five vCJD CJD patients, giving a sensitiv-
ity of 24% (95%CI: 10-45%) [49]. 
 
Tau proteins occur in axons in the central nerv-
ous system and are associated with micro-
tubules. They are known to become hyperphos-
phorylated in neurodegenerative conditions, 
such as Alzheimer’s. The link to vCJD was dem-
onstrated by Tagliavini, who found phosphory-
lated tau immunoreactive neuritic profiles sur-
rounding PrP deposits in patients with vCJD 
[51]. In Sanchez-Juan’s paper elevated total tau 
proteins showed a sensitivity of just 24% (95% 
CI 16-35%) using a cut off of greater than 
1,300pg/ml [49]. Elevated total tau was found 
in 21 of 86 patients tested. However, sensitivi-
ties of 80% were shown when using a cut off of 
greater than 500pg/ml. Green et al used a total 
CSF tau of >400pg/ml as the cut off in their 
2006 paper [52]. In addition phosphorylated 
tau was also assessed. 51 vCJD and 37 control 
cases were included in the study, along with 50 
sCJD cases and 46 sCJD controls. The control 
cases had been suspected as having the condi-
tions, but the diagnoses had been excluded by 
either another diagnosis being reached or their 
recovery. Interestingly, although levels of CSF 
tau were highest in the sCJD group, the level of 
phosphorylated tau was highest among vCJD 
cases. CSF tau (>400pg/ml) was 90% sensitive 
and 89% specific in vCJD CJD. Phosphorylated 
tau was found to be 84% sensitive and 86% 
specific in this study. The ratio of tau protein to 
phosphorylated tau could also be useful in dif-
ferentiating vCJD from sCJD, its most common 
differential diagnosis. Likewise in small studies, 
CSF Apolipoprotein E and uric acid levels have 
also been suggested as useful discriminators 
between these types of CJD, but not other con-
ditions [53,54].  However, another investigation 
is better at doing this: MR brain imaging.   
 
Neurological investigations in vCJD 
 
The pattern of investigations in vCJD differs 
from sCJD. Typical electroencephalogram (EEG) 
findings of periodic complexes have only rarely 
been reported  in vCJD and then only in the final 
stages of illness [55]. High signal in the pulvinar 
area of the thalamus bilaterally on T2 weighted 
MR imaging is seen in vCJD. Collie et al [56] 
established that fluid-attenuated inversion re-
covery and diffusion weighted MRI sequences 
were better than standard T2 sequences at 
demonstrating the high signal. By including 
these new sequences the “pulvinar sign” had a 
sensitivity of 90%, occurring in 74 out of 82. 
The pulvinar sign is currently said to be 78-90% 
sensitivity and is highly specific. There have 
however been three reported sCJD cases with 
the MV genotype and predominant pulvinar high 
sign on MRI [57].  Another potentially useful in-
vestigation is tonsil biopsy. In advanced disease 
it appears to be a sensitive investigation. How-
ever, there is the small possibility of misdiag-
nosing a patient with sub-clinical disease and 
there are risks from the procedure, particularly 
in obtunded patients [58]. 
 
Conclusion 
 
With the control of the BSE epidemic in the UK 
we have seen an encouraging fall in the inci-
dence of vCJD. The precautionary measures in 
beef production and processing have reduced 
the risk of further vCJD cases developing 
through dietary exposure to BSE. There is how-
ever, the possibility of an increased incubation 
period in older patients and those with PRNP-
129 MV and VV genotypes exposed in the die-
tary at risk period. Early diagnosis of any such 
patients remains important to reduce the possi-
bility of secondary transmission of the condition 
via blood donation or surgical procedures. An 
effective screening test, preferably from blood, 
is yet to be developed. Progress is being made 
towards this with a recent publication on an 
assay for detecting vCJD infection in blood [59]. 
This involves abnormal PrP being absorbed and 
concentrated on stainless steel particles, before 
being detected with a PrP-specific antibody fol-
lowed by an ELISA coupled with chemilumines-
cent detection. The assay detected 15 of 21 
blood samples from patients with clinically ap-
parent vCJD; all 169 control patients were nega-
tive. This will be difficult for others to replicate 
at present as some of the details of the method-
The molecular epidemiology of variant CJD  
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ology were not explicitly supplied [60]. Although 
the techniques may improve, as a diagnostic 
tests, its sensitivity is currently far lower than 
that of brain MRI. Larger numbers of samples 
from healthy individuals would need to be 
tested to determine the specificity of the assay 
before it could be considered for blood screen-
ing. It is also unclear whether the assay will de-
tect the level of infectivity seen in asymptomatic 
patients with vCJD in their lymphoid tissues. 
There is the possibility that some people may 
have truly sub-clinical infection (ie they may 
never develop neurological disease). Therefore, 
even if the assay could detect infectivity in 
these individuals it would be difficult to know 
how to advise them following positive results. 
Such uncertainty could conceivably affect blood 
donation numbers. Therefore, their findings are 
interesting and may lead to further develop-
ments, but there are a number of issues that 
still need to be addressed. On the positive side 
the transmissibility and natural occurrence of 
prion diseases in animals makes them amena-
ble to further scientific study. Progress is ongo-
ing in our understanding of these conditions 
and prion biology in general.    
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